3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Spinocerebellar Degenerations
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Colorectal Neoplasms
1
Interventions
Paclitaxel
489
Carboplatin
435
Gemcitabine
394
Docetaxel
385
Cisplatin
359
pembrolizumab
343
Bevacizumab
335
Nivolumab
261
Pemetrexed
242
Capecitabine
221
Dexamethasone
213
Fluorouracil
211
Rituximab
203
Trastuzumab
193
Cyclophosphamide
190
Oxaliplatin
160
Erlotinib Hydrochloride
147
Ipilimumab
145
atezolizumab
144
Prednisone
144
Cetuximab
142
Irinotecan
139
Leucovorin
130
Doxorubicin
130
Sorafenib
120
Lenalidomide
119
Bortezomib
118
Sunitinib
107
Everolimus
93
130-nm albumin-bound paclitaxel
91
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
vicriviroc
×
Clear all
NCT03631407
2024-11-21
MK-7690-046
Merck Sharp & Dohme LLC
Phase 2
Completed
41 enrolled
20 charts